Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease

Summary

Moonwalk Biosciences secured $70 million in financing to develop RNAi-based siRNA therapies targeting obesity and cardiometabolic disease while expanding its drug discovery platform. The funding will support pipeline expansion with a focus on adipose tissue-targeting medicines.